Diranersen is an experimental gene-silencing therapy that stops brain cells from making new tau proteins. It is delivered via intraspinal injection and in the Phase 2 trial, showed promising signs that it might slow cognitive decline and clear out toxic tau tangles in early Alzheimer’s. A Phase 3 trial is needed to confirm whether it is effective.